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As it is known that genetic polymorphisms of glutathione S-transferases (GST) have been associated with a variety of human diseases including cancer, we have analyzed the impact of GSTT1 and GSTM1 null genotypes on the risk of development of differentiated thyroid cancer (DTC) and cytogenetic changes in peripheral blood lymphocytes of DTC patients before and after radioiodine therapy. The polymorphism of GSTT1 and GSTM1 genes were genotyped using multiplex polymerase chain reaction (PCR) and cytokinesis -block micronucleus (MN) assay to assess cytogenetic changes. GSTT1 and GSTM1 null were predominantly found in patients, but statistical significance was observed only for GSTT1 null. The null genotypes increased risk of development of DTC; GSTT1 null a 4.5 times (p < 0.05), GSTM1 null about 3 times but on the border of statistical significance (p = 0.057), while combination of dual null genotypes almost 7 times (p < 0.05) increased risk. No significant effects of the null genotypes as well as their interactions with potential modifiers of MN (diagnose, age, gender and smoking habits) were observed on both baseline and radioiodine-induced values of MN and cytokinesis block proliferation index (CBPI) in DTC patients. Results suggest that both GSTT1 and GSTM1 null genotypes increased risk for DTC but to a greater extent GSTT1 null. Null genotypes of GSTT1 and GSTM1 did not have potential to influence baseline and radioiodineINTRODUCTION Thyroid cancer is the most common endocrine cancer (JEMAL et al., 2010) . Incidence of this cancer continuously increases, which can be associated with greater exposure to numerous agents including the first exposure to ionizing radiation as well as numerous other agents which may act as genotoxic carcinogens (PELLEGRITI et al., 2013) . Numerous epidemiological studies examined the effect of ethic, geographic and dietary factors on the risk of thyroid cancer. Studies aimed at diet and lifestyle provided controversial results because these factors may change in the same individual over time (MACK et al., 2003) ; interestingly, there are studies that showed a reduction of thyroid cancer risk in women smokers (KREIGER and PARKES, 2000; STRANGE et al., 2000) .
Differentiated thyroid cancers (DTCs) derive from follicular cells of the thyroid gland and include papillary and follicular cancers (BOYCE, 1995) . Initial treatment of these patients includes total or near total thyroidectomy and radioiodine therapy (SCHLUMBERGER and SHERMAN, 2012) . In the previous study using the micronucleus (MN) assay we demonstrated cytogenetic damage in lymphocytes in DTC patients before and after radioiodine therapy in comparison to healthy controls (p < 0.001). We also demonstrated that baseline cytokinesis block proliferation index (CBPI) in the patients were significantly lower than in controls (p < 0.05) and that after radioiodine therapy these values further reduced (p < 0.001) (VRNDIĆ et al., 2013) .
The role of MN as the intermediate endpoint of carcinogenesis occurs in a number of published papers, which showed a significant increase in MN frequencies (VARGA et al., 2006; BONASSI et al., 2007; MILOŠEVIĆ-DJORDJEVIĆ et al., 2010) . Recent studies have shown that changes in both metabolic capacity and DNA repair system can significantly change the sensitivity of individuals on the effect of genotoxic agents and thus significantly increase the risk of cancer (HO et al., 2006; XIANG et al., 2012) .
Glutathione S-transferase (GST) system consists of a large group of detoxifying enzymes involved in the metabolism of xenobiotics (JANACOVA et al., 2010) whose activity is reflected in the catalyzing the glutathione conjugation of genotoxic compounds with electrophilic functional groups to prevent adduct formation and thus protect cells from DNA damage (MANNERVIK, 1985) .
In humans, GSTs have been grouped into eight classes of isoenzymes Alpha, Mu, Pi, Sigma, Omega, Theta, Zeta and Kappa and each class can include several genes (PARL, 2005) . Null genotypes of GSTT1 and GSTM1 genes result in total loss of enzyme activity and reactive metabolites will not detoxify and can act with DNA.
Many studies have investigated the effects of GSTT1 and GSTM1 null on cancer risk, but the results are controversial. So, JOSEPH et al. (2004) reported increased frequencies of GSTT1 and GSTM1 null genotypes in the children with acute lymphoblastic leukemia and CHACKO et al. (2005) reported similar results in the breast cancer patients. JAIN et al. (2006) analyzing association of GSTT1 and GSTM1 polymorphisms and environmental exposures on susceptibility for development of esophageal cancer in North Indian population indicated that deletions of studied genes were not associated with higher risk for esophageal cancer, but interaction of smoking or alcohol and GSTM1 null genotype moderately increased risk. An association of the GSTT1 and GSTM1 null genotypes and significantly increases the risk only for DTC but not for benign thyroid tumors, reported by HO et al. (2006) .
We hypothesized that limited ability for detoxification of carcinogens due to absence of GSTT1 and GSTM1 isoenzymes causes increased sensitivity of cells to the mutagen effects of administered therapy. The aim of this study was to examine the association of total deletions (null) of GSTT1 and GSTM1 genes polymorphisms with DTC and cytogenetic damage in peripheral blood lymphocytes (PBLs) of DTC patients before and after radioiodine therapy treatment.
MATERIALS AND METHODS

Study population
The study population included 26 well-DTC patients of mean age 52.04 ± 14.18 years and 33 control subjects of mean age 45.91 ± 11.4 years ( Table 1 ). All patients after thyroidectomy were treated at the Nuclear Medicine Department of the Clinical Center Kragujevac with fixed nominal activities of 3.7 GBq (100mCi) of orally administered radioiodine according to EANM guidelines (LUSTER et al., 2008) . The controls were colleagues who were free of any kind of malignancy and who had not been exposed to radioactive sources or other known genotoxic agents of 3 months before. Peripheral blood samples were obtained twice from the patients, before and after radioiodine treatment, while blood samples from controls were taken only once. After collecting, blood samples were kept at 4 o C and for genotyping were stored at -20 o C until use. The study was approved by the Ethical Committee of the Clinical Centre Kragujevac. All patients and control subjects gave written informed consent according to the Helsinki Declaration. 
DNA isolation and genotyping of GSTT1 and GSTM1 genes
Genomic DNA was isolated from 350 µl of whole blood using the EZI DNA Blood 350 µl Kit (Qiagen, Hilden, Germany) and BioRobot EZ1, following the manufacturer ' s instructions. The genetic polymorphism analysis for the GSTT1 and GSTM1 genes was determined using the multiplex polymerase chain reaction (PCR) method described by ABDEL-RAHMAN et al. (1996) with some modifications. For detection of GSTT1 gene polymorphism the amplified product is 480 base pairs in length, while absence of this product is indicative of the deletion. For detection of the GSTM1 gene polymorphism the amplified product is 215 base pairs in length, and absence of this product is indicative of the deletion. Positive control was exon 7 of CYP1A1 and the amplified product is 312 base pairs in length.
The DNA products were amplified with primers (Invitrogen, California, 
Cytokinesis-block micronucleus (MN) assay
Cytokinesis -block micronucleus (MN) assay was carried out using the procedure described by FENECH (2000) . Whole heparinized blood (0.5 ml) was added to 5 ml of the RPMI medium contains fetal bovine serum, L-glutamine and phytohemaglutinin (complete GIBCO TM PB-Max TM karyotyping medium; Invitrogen, California, USA). Cultures were incubated at 37 o C for 72 hrs. On the forty fourth hour after the beginning of incubation, cytochalasin B (Sigma, St. Louis, MO, USA) was added in the final concentration of 4 μg/ml. Cultures were harvested 28 hrs later. The cells were collected by centrifugation, treated with cold (4 o C) hypotonic solution (0.56% KCl) and fixed with fixative methanol: glacial acetic acid = 3:1. The cell suspensions were dropped onto clean slides, lamp-dried and stained with 2% Giemsa (Alfapanon, Novi Sad, Serbia).
The analysis of MN was performed using a light microscope (Nikon E50i) at 400x magnification following the criteria for MN scoring in binucleated (BN) cells only, described by FENECH (2007) . One thousand BN cells per subject examined for MN scoring and one thousand viable cells from each subject were scored to determine the number of cells with 1, 2, 3 and 4 nuclei for calculation of cytokinesis-block proliferation index (CBPI). CBPI was calculated using the formula CBPI = (M1 + [2 x M2] + 3 x [M3 + M4])/ N, where M1 -M4 are the numbers of cells with 1 to 4 nuclei and N is the total number of viable scored cells (FENECH, 2007) .
Statistical analyses
The commercial SPSS version 16.00 for Windows was used for statistical analyses. For comparing distribution of GSTT1 and GSTM1 genotypes the chi-square (χ 2 ) or Fischer , s (F) exact test were used. The Odds Ratio (OR) with 95% confidence interval (CI) calculated by binary logistic regression analyses was used to illustrate association between GSTT1 and GSTM1 null genotypes and DTC risk. All values for MN and CBPI were expressed as mean ± standard deviation (S.D.). Student , s t-test was employed for comparison of mean values of baseline and radioiodine-induced cytogenetic biomarkers in patients. Additionally, multiple regression analyses were performed for analyzing the influence of variables such as diagnose, age, gender, smoking habits and GSTT1 null and GSTM1 null genotypes on MN and CBPI values. Probability less than 0.05 was set up as significant. Table 2 shows summarized distributions of both GST genes T1 and M1, individually and in combinations, in DTC patients and controls. GSTT1 and GSTM1 null genotypes were predominantly found in DTC patients (38.5% and 61.5% in DTC patients vs. 12.1% and 36.4% in controls), but statistical significance was observed only for GSTT1 null (p < 0.05). The GSTT1 null genotype showed an increased risk for DTC (OR = 4.53, 95% CI = 1.22 -16.8, p < 0.05) while GSTM1 null increased risk for DTC, but on the border of statistical significance (OR = 2.8, 95% CI = 0.97 -8.09, p = 0.057). Considering combinations of GSTT1 and GSTM1 genotypes about 23% of patients and 61% of controls had dual GSTT1/GSTM1 positive combination, which was a significant difference (p < 0.001). There were no significant differences in the frequency of GSTT1positive/GSTM1null, GSTT1null/GSTM1positive and dual GSTT1/GSTM1 null combinations between DTC patients and controls (p > 0.05), but the total of combinations with one and dual null genotypes was significantly higher in patients than in controls (76.9% vs. 39.4%, p < 0.05). Using the dual GSTT1/GSTM1 positive combination as reference, there were significantly risk for DTC with combinations with one or both null T1 and M1 genotypes (OR = 3.7, 95% CI = 1.03 -13.35, p < 0.05; OR = 13.33, 95% CI = 1.24 -143.15, p < 0.05; OR = 6.67, 95% CI =1.27 -35.04, p < 0.05). Table 3 summarizes the influences of GSTT1 and GSTM1 genotypes on both values MN and CBPI in DTC patients. The MN frequencies and CBPI values were stratified relevant to status of genotypes. No significant effects of GSTT1 and GSTM1 null genotypes, alone and in combinations with one and dual null, were observed on baseline and radioiodine-increased MN frequencies. According to the genotype status on CBPI our results showed that neither of analyzed null genotypes, alone and in combinations, influenced the baseline and therapydecreased CBPI values. The multiple regression analyses for MN and CBPI in DTC patients which included interactions of GSTT1 and GSTM1 null genotypes with variables diagnose, age, gender and smoking habits (Tables 4 and 5 ), showed that both baseline and radioiodine-induced values of MN and CBPI in DTC patients were not affected by GSTT1 and GSTM1 null genotypes. Namely, the therapy-increased MN frequencies were associated only with baseline MN (Table 4) , while the therapy-decreased CBPI values were affected by interaction between gender, smoking habits and baseline CBPI (Table 5) .
RESULTS AND DISCUSSION
Table 5. Results of multiple regression analysis for citokinesis-block proliferation index (CBPI) including
GSTT1 and GSTM1 status and potential modifiers of CBPI DISCUSSION Numerous literature data suggested importance of GST genes in defense against endogenously agents (CHEN et al., 2010; KUMAR et al., 2011) and that their mutations could associate with different diseases (MANFREDI et al., 2007; MUSTAFA et al., 2010) especially with cancer (ATES et al., 2005; HO et al., 2006; SINGH et al., 2008) .
In this study we investigated the effects of GSTT1 and GSTM1 null genotypes on the risk of development of DTC and both baseline and radioiodine-induced cytogenetic damage in PBLs of DTC patients.
The study of the individual roles of GSTT1 and GSTM1 genes revealed significantly higher frequency of GSTT1 null genotype in DTC patients than in controls (38.5% vs. 12.1%). We found that the GSTT1 null genotype was significantly associated with high risk of DTC (OR = 4.53, p < 0.05). These findings are consistent with the report of SIRAJ et al. (2008) who concluded that the GSTT1 null genotype showed a 3.48 times higher risk of DTC. However, although a greater percentage of patients had GSTM1 null genotype, this genotype on the border of statistical significance was associated with almost three times increased risk for DTC (OR = 2.80, p = 0.057). Another thyroid cancer studies showed that only combination with dual GSTT1/GSTM1 null genotype significantly increased the risk for thyroid cancer (MORARI et HO et al., 2006) . Our results showed that all of the combinations with one or dual null genotype significantly increased the risk for DTC and that the individuals with dual null GSTT1/GSTM1 genotypes had an almost 7-fold increased risk for DTC. DTC patients had significantly higher frequency of combinations with one null or dual null genotypes than controls (p < 0.05), whereas the frequency of combination with dual positive genotypes was significantly higher in controls than in patients (p < 0.05).
The role of genetic factors in the research of susceptibility to carcinogen effects of various agents has been the subject of many studies and micronuclei (MN) frequency is the most frequently used endpoints (BONASSI et al., 2005) . Some studies demonstrated the increase of baseline MN levels in GSTT1 null subjects. Thus KADIOGLU et al. (2012) evaluated the relationship between chromosomal aberrations (CA), CBMN, and modified comet assay and metabolic GST genes, as well as mutagen sensitivity in cultured lymphocytes of healthy volunteers. They showed that the GSTT1 null genotype significantly elevated baseline levels of CA and MN in respect to the positive genotype, and that GSTM1 null and GSTP1 mutant genotypes did not result in any differences in studied cytogenetic parameters. Similarly, TUIMALA et al. (2004) reported that GSTT1 null genotype was associated with significant increase in baseline frequency of CA in unexposed individuals. On the contrary, HERNANDEZ et al. (2006) studied the association between GSTs (T1, M1, P1) and MN frequency in lymphocytes of thyroid cancer patients, reported that both baseline and increased MN frequency after therapy exposure were not associated with the GST genotypes.
Our results did not show the association between GSTT1 and GSTM1 null genotypes and both baseline and therapy-increased MN frequencies in PBLs of patients. Analyzing the association between CBPI values and GST polymorphisms, we concluded that both baseline and decreased CBPI values after therapy were not associated with GSTT1 and GSTM1 null genotypes.
Numerous studies showed that genetic instability of cells was based on the state of health and a causal association between MN frequency and a cancer risk (BONASSI et al., 2007; VARGA et al., 2006; MILOŠEVIĆ-DJORDJEVIĆ et al., 2010) .
We do not know of the previously reported data about the associated GST polymorphisms and radioiodine therapy-induced cytogenetic parameters except for one study, done by HERNANDEZ et al. (2006) . The first report of the association between genetic polymorphism and cytogenetic response to genotoxic exposure in vivo was given by VAN POPPEL et al. (1992) who reported that slightly increased SCEs in heavy smokers was not expressed in GSTM1 genotype. On the other hand, the same author (VAN POPPEL et al., 1994) analyzed the MN frequency in sputum cells of smokers and concluded that this frequency was not influenced by GSTM1. More recent studies on occupationally or environmentally exposed individuals showed that higher MN frequency was associated with GSTT1 null genotype (LAFFON et al., 2006; KUMAR et al., 2011) . However, KIRSCH-VOLDERS et al. (2006) reported lower MN frequency in the occupationally exposed individuals with GSTT1 and GSTM1 null genotypes. Our results showed that patients with GSTT1 null genotype had lower baseline and radioiodine-induced MN frequencies in comparison to their positive counterparts, but without statistical significance. On the contrary, patients with GSTM1 null genotype had no significantly higher baseline and therapy induced MN frequencies in respect to the positive genotype.
When diagnose, age, gender and smoking habits implicated as the potential modifiers of MN frequency (BONASSI et al., 2003; MILOŠEVIĆ-DJORDJEVIĆ et al., 2005) in interacting with genotypes, we also found that GSTT1 and GSTM1 null genotypes were not associated with both values MN and CBPI in PBLs of DTC patients before and after therapy. Multiple regression analyses showed that both baseline values, for MN significantly higher and for CBPI significantly lower than in controls (VRNDIĆ et al., 2013) , were associated only with diagnose (health condition), while increased values of MN after therapy were associated only with baseline values. On the contrary, CBPI values after therapy decreased and this decrease associated with interaction between genders, smoking habits and baseline CBPI.
The number of DTC patients analyzed in this study (n = 26) is a consequence of a relatively low incidence of thyroid carcinomas, which represent 1-2% of all malignant tumors (SIPOS and MAZZAFERRI, 2010) and criteria for their inclusion in the study (COOPER et al., 2009; SCHLUMBERGER and SHERMAN, 2012) . Namely, in this study we analyzed only patients selected for radioiodine therapy. According to the American Thyroid Association (ATA) recommendations, radioiodine therapy is indicated in patients with moderate to high risk of recurrence based on age, tumor size, lymph node status, extra-thyroidal extension, and the histological type of the thyroid tumor. The association of GSTT1 and GSTM1 polymorphisms with both DT carcinomas and cytogenetic damage in PBLs of patients (baseline and induced) was demonstrated for the first time. This is especially important if one bears in mind that the incidence of DTCs is increased during last 30 years (DAVIES and WELCH, 2006; GRINIATSOS et al., 2009; KOLFOY et al., 2009 ).
CONCLUSION
The general conclusion is that the presence of the GSTT1 and GSTM1 null genotypes is associated with an increased risk for development of DTC, but GSTT1 null to a greater extent. Cytogenetic changes in PBLs of DTC patients before and after radioiodine therapy (MN frequency and CBPI) were not under the influence of GSTT1 and GSTM1 null genotypes (alone or in their combinations), so that the absence of T1 and M1 isoenzymes did not cause increased mutagen sensitivity of PBLs of DTC patients.
